{
    "clinical_study": {
        "@rank": "67357", 
        "brief_summary": {
            "textblock": "RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing\n      so they stop growing or die.\n\n      PURPOSE: Phase II trial to study the effectiveness of gemcitabine in treating women with\n      metastatic breast cancer previously treated with doxorubicin and paclitaxel."
        }, 
        "brief_title": "Gemcitabine in Treating Women With Metastatic Breast Cancer Previously Treated With Doxorubicin and Paclitaxel", 
        "completion_date": {
            "#text": "November 2002", 
            "@type": "Actual"
        }, 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Determine the objective response rate to gemcitabine in women with metastatic breast\n           cancer previously treated with two to four chemotherapy regimens, including doxorubicin\n           and paclitaxel.\n\n        -  Characterize the nature of toxicity of gemcitabine in this patient population.\n\n        -  Determine the response duration to gemcitabine in this patient population.\n\n      OUTLINE: Patients receive gemcitabine IV over 30 minutes once weekly for 3 consecutive weeks\n      (days 1, 8, and 15) followed by 1 week of rest. Treatment continues every 4 weeks in the\n      absence of disease progression or unacceptable toxic effects.\n\n      Patients are followed until death.\n\n      PROJECTED ACCRUAL: A total of 14-30 patients will be accrued for this study within 13\n      months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Histologically confirmed metastatic breast cancer\n\n          -  Bidimensionally measurable disease\n\n               -  No bone scan abnormalities alone\n\n               -  Lytic lesions in conjunction with bone scan abnormalities allowed\n\n               -  No pure blastic bone metastases\n\n               -  No pleural or peritoneal effusions\n\n               -  No previously irradiated lesions\n\n          -  Must have received 2-4 prior chemotherapy regimens, including paclitaxel and\n             doxorubicin, for breast cancer\n\n          -  Brain metastases allowed if other measurable disease exists\n\n               -  No uncontrolled or life threatening brain lesions\n\n          -  No carcinomatous meningitis\n\n          -  Hormone receptor status:\n\n               -  Not specified\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  18 and over\n\n        Sex:\n\n          -  Female\n\n        Menopausal status:\n\n          -  Not specified\n\n        Performance status:\n\n          -  Karnofsky 60-100%\n\n        Life expectancy:\n\n          -  Not specified\n\n        Hematopoietic:\n\n          -  Granulocyte count at least 1,500/mm^3\n\n          -  Platelet count at least 100,000/mm^3\n\n        Hepatic:\n\n          -  AST/ALT no greater than 5 times upper limit of normal\n\n        Renal:\n\n          -  Calcium no greater than 11.0 mg/dL\n\n        Other:\n\n          -  Not pregnant\n\n          -  Negative pregnancy test\n\n          -  No history of other malignancy except carcinoma in situ of the cervix or curatively\n             treated nonmelanoma skin cancer\n\n          -  No other serious medical illnesses, including severe infection and severe\n             malnutrition\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  Not specified\n\n        Chemotherapy:\n\n          -  See Disease Characteristics\n\n          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas and mitomycin)\n             and recovered\n\n          -  No other concurrent chemotherapy\n\n        Endocrine therapy:\n\n          -  Prior hormonal therapies for stage IV disease and/or adjuvant therapy allowed\n\n          -  At least 3 weeks since prior hormonal therapy\n\n        Radiotherapy:\n\n          -  See Disease Characteristics\n\n          -  No prior radiotherapy to greater than 30% of the marrow bearing bone\n\n          -  At least 4 weeks since prior radiotherapy and recovered\n\n          -  No concurrent radiotherapy to the only measurable lesion\n\n        Surgery:\n\n          -  Recovered from prior surgery\n\n          -  No concurrent surgery to the only measurable lesion\n\n        Other:\n\n          -  No concurrent nonprotocol treatment"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 1, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00003540", 
            "org_study_id": "98-030", 
            "secondary_id": [
                "CDR0000066594", 
                "NCI-G98-1474"
            ]
        }, 
        "intervention": {
            "intervention_name": "gemcitabine hydrochloride", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Gemcitabine"
        }, 
        "keyword": [
            "stage IV breast cancer", 
            "recurrent breast cancer"
        ], 
        "lastchanged_date": "June 24, 2013", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/MSKCC-98030"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10021"
                }, 
                "name": "Memorial Sloan-Kettering Cancer Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Phase II Study of Gemcitabine in the Treatment of Patients With Metastatic Breast Cancer Previously Treated With Adriamycin and Taxol", 
        "overall_official": {
            "affiliation": "Memorial Sloan-Kettering Cancer Center", 
            "last_name": "Violante E. Currie, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2002", 
            "@type": "Actual"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00003540"
        }, 
        "source": "Memorial Sloan-Kettering Cancer Center", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Memorial Sloan-Kettering Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 1998", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }, 
    "geocoordinates": {
        "Memorial Sloan-Kettering Cancer Center": "40.714 -74.006"
    }
}